Compare Nvidia Corp (NVDA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Tango Therapeutics Inc. — how do they compare? Nvidia Corp trades at $217.24 (market cap $5.34T), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Nvidia Corp is far larger — about 1427.8× Tango Therapeutics Inc.'s market cap, and Nvidia Corp pays a 0.45% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 116 Days and Tango Therapeutics Inc. for 0 Days on average.
| NVDA | TNGX | |
|---|---|---|
Market Cap | $5.34T | $3.74B |
Volume | 117,762,243 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $239.27 | $32.90 |
52-Week Low | $165.17 | $7.50 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $5.32T | $2.76B |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 63.66% net income margin and 117.21% ROE. The stock shows bullish technical signals with recent earnings beats and analyst consensus price target of $339.17 representing 48% upside potential. Revenue growth accelerated to $130.5B in 2025 with projected $303B for 2026.
NVIDIA maintains dominant AI market position with robust financials, though elevated valuations (P/E 27.98, P/S 17.82) and competition pose risks. Strong institutional support (75.95% buy ratings) and cash flow growth support long-term outlook, but investors should monitor execution against high expectations and market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
